Orgenesis

ORGCAR19 (CD19 CAR-T)

B-ALL, Lymphoma

An advanced monomeric anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) therapy to treat relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) patients.

MOTC (Metabolic Optimized T-Cells)

Lung Cancer; Melanoma

An anti-cancer cellular vaccine that utilizes patient antigen presenting cells (APCs) pulsed with relevant cancer cells to target the entire repertoire of tumour cell antigens and elicit immune response against hard to treat cancers.

DUVAC (Cellular vaccine)

Solid Tumors; Pancreatic Cancer

An adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) as a personalized cancer treatment platform via infusion of autologous T lymphocytes expanded from tumors. A complementary cellular biomanufacturing platform is being developed based on a novel metabolic sensor to optimize the harvest time and increase therapeutic potential of the T-cells.

ORGCAR19.22 (CD19.22 CAR-T)

B-ALL

A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.

CAR-NK

Multiple Myeloma, Ovarian Cancer

A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.

RanTop

HPV: Genital Warts; Anal Dysplasia

Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.

SVF-COV

Covid-19 Related ARDS

Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.

AutoVac

Covid-19 Vaccine

A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.

Kyslecel™

Chronic Pancreatitis

Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.

Bioxome™

Liver, Kidney and Dermatological Diseases

A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.

MSCP

Psoriasis; Wound Healing

A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.

Cartil-S/Chondroseal

Osteoarthritis

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

SVF-CLI/ED

Erectile Dysfunction, CLI

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

Rev-md

Musculoskeletal Diseases

Synthetic exosomes/extracellular vesicles that have demonstrated the ability to fuse with cell membranes and deliver intracellular cargo in a similar manner to natural exosomes. Bioxome can carry selected therapeutic cargo inside target cells, to induce a variety of therapeutic applications. Currently developed to treat Kidney and Liver Disorders.

MSCKD

Acute and Chronic Kidney Diseases

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

EVs

Chronic Kidney Diseases

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

POCare Platform

Orgenesis Mobile Processing Units and Labs™

POCare Therapies

POCare Technology

POCare Network

Overview

Orgenesis

Investor Documents

Investor Presentation

2023 Annual Filing

Therapies Pipeline

Company Info

Industry Classifications

Frequently Asked Questions

What is Orgenesis Inc.'s stock symbol?

When was Orgenesis Inc. incorporated?

When did Orgenesis Inc. become a public company?

When is Orgenesis Inc.'s fiscal year end?

Who is Orgenesis Inc.'s transfer agent?

Who is Orgenesis Inc.'s independent auditor?

Who is Orgenesis Inc.'s outside legal counsel?